October 18, 2007 – XTENT Inc. announced that two-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company’s investigational Custom NX drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

October 17, 2007 - CryoCor, Inc., a medical device company focused on the treatment of cardiac arrhythmias, announced today that CryoCath Technologies Inc. has filed a lawsuit against CryoCor in the United States District Court for the District of Delaware alleging that CryoCor infringes several of CryoCath’s U.S. patents.

October 17, 2007 — Patients with heart disease who undergo coronary angioplasty have an equivalent risk of death and heart attack as patients who undergo coronary bypass surgery, according to Stanford University School of Medicine researchers.

October 17, 2007 — The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Medical Center, one of only 80 sites around the world joining in the study.

Medicated, drug-coated stents have been used with great success for the past several years in treating coronary artery disease.

October 17, 2007 - Boston Scientific Corp. will be presenting safety and efficacy data on its TAXUS Express2 and TAXUS Liberte Paclitaxel-Eluting Stent Systems at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 20-25, 2007, in order to reinforce the safety of the stent systems.

October 17, 2007 - Compared to bare metal stents, in patients with acute myocardial infarction, sirolimus-eluting stent (SES) implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery, Japanese researchers report in the October 2nd issue of the Journal of the American College of Cardiology.

Kiyotaka Kugiyama, M.D., and colleagues at the University of Yamanashi, Chuo City note that drug-eluting stents reduce restenosis rates and revascularization but may impair recovery from reperfusion-induced endothelial injury.

October 17, 2007 - After a three-week trial, a jury rendered a verdict of "willful" patent infringement in a dispute filed against CHF Technologies, Inc., d/b/a BioVentrix, after Chase Medical sued BioVentrix alleging its Blue Egg Sizer, a hollow, blue silicone device used to guide surgeons in surgically resizing the heart, infringed patents held by Chase.

October 17, 2007 - Positron Corp. introduced its new dedicated-Cardiac PET system, Attrius, at the annual meeting of the American Society of Nuclear cardiology, for which it expects to receive 510k FDA approval in spring of 2008 in time for proposed cardiac PET reimbursement increase on Jan 1, 2008.

October 17, 2007 – Siemens Medical Solutions today announced that it recently received FDA 510(k) clearance for a 1.5 Tesla (T) magnetic resonance imaging (MRI) system that is reportedly more affordable, allowing providers to upgrade from low-field MRI systems or to add an MRI system for the first time.
The cost of the new 1.5T MAGNETOM Essenza can reportedly be as much as $500,000 less than other 1.5T systems, making it possible for small hospitals and diagnostic imaging centers to offer a new range of imaging services.

The FDA gave ZOLL Medical Corp., a manufacturer of resuscitation devices and related software solutions, clearance to market and sell the ZOLL AED Pro with See-Thru CPR technology, which is designed to help minimize interruptions in CPR.
ZOLL aims to comply with a key recommendation of the American Heart Association’s Guidelines for Advanced Cardiac Life Support.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now